Pancreas

FDA approves daraxonrasib, a first-in-class RAS inhibitor, in previously treated metastatic pancreatic cancer

On 26 August 2026 the FDA approved daraxonrasib (Rasonque), a first-in-class inhibitor of RAS proteins, for adults with metastatic pancreatic ductal adenocarcinoma after at least one prior systemic therapy or who are not candidates for multiagent chemotherapy. In the randomised phase 3 RASolute 302 …